Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 5 of 5 publications.

Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24

Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774

Dardis G, Tryon R, Ton Q, Johnson SL, Lovine MK. Cx43 suppresses evx1 expression to regulate joint initiation in the regenerating fin. Dev Dyn. 2017 Sep;246(9):691-9. doi: 10.1002/dvdy.24531

Hansen MK, Gammelager H, Jacobsen CJ, Hjortdal VE, Layton JB, Rasmussen BS, Andreasen JJ, Johnsen SP, Christiansen CF. Acute kidney injury and long-term risk of cardiovascular events after cardiac surgery: a population-based cohort study. J Cardiothorac Vasc Anesth. 2015 Jun;29(3):617-25. doi: 10.1053/j.jvca.2014.08.020

Slotkin JR, Chakrabarti L, Dai HN, Carney RSE, Hirata T, Bregman BS, Gallicano GI, Corbin JG, Haydar TF. In vivo quantum dot labeling of mammalian stem and progenitor cells. Dev Dyn. 2007 Dec;236(12):3393-401. doi: 10.1002/dvdy.21235